Recombinant multi-species CDKN2B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CDKN2B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported. [provided by RefSeq, Jul 2008]
The Alternative Names of target: CDK4I,CDKN2B,Cdkn2b,Cyclin-dependent kinase 4 inhibitor B,INK4B,INK4b,MTS2,Multiple tumor suppressor 2 (MTS-2),P15,TP15,p14-INK4b,p15,p15(INK4b),p15-INK4b (p15INK4B),p15INK4B,p15INK4b

Target products collectionGo to CDKN2B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP3470-Ag-1/ GM-Tg-hg-IP3470-Ag-2 Human CDKN2B protein Human
GM-Tg-rg-IP3470-Ag-1/ GM-Tg-rg-IP3470-Ag-2 Rat CDKN2B protein Rat
GM-Tg-mg-IP3470-Ag-1/ GM-Tg-mg-IP3470-Ag-2 Mouse CDKN2B protein Mouse
GM-Tg-cynog-IP3470-Ag-1/ GM-Tg-cynog-IP3470-Ag-2 Cynomolgus/Rhesus macaque CDKN2B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP3470-Ag-1/ GM-Tg-felg-IP3470-Ag-2 Feline CDKN2B protein Feline
GM-Tg-cang-IP3470-Ag-1/ GM-Tg-cang-IP3470-Ag-2 Canine CDKN2B protein Canine
GM-Tg-bovg-IP3470-Ag-1/ GM-Tg-bovg-IP3470-Ag-2 Bovine CDKN2B protein Bovine
GM-Tg-equg-IP3470-Ag-1/ GM-Tg-equg-IP3470-Ag-2 Equine CDKN2B protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP3470-Ag-1/ GM-Tg-hg-IP3470-Ag-2; GM-Tg-rg-IP3470-Ag-1/ GM-Tg-rg-IP3470-Ag-2;
GM-Tg-mg-IP3470-Ag-1/ GM-Tg-mg-IP3470-Ag-2; GM-Tg-cynog-IP3470-Ag-1/ GM-Tg-cynog-IP3470-Ag-2;
GM-Tg-felg-IP3470-Ag-1/ GM-Tg-felg-IP3470-Ag-2; GM-Tg-cang-IP3470-Ag-1/ GM-Tg-cang-IP3470-Ag-2;
GM-Tg-bovg-IP3470-Ag-1/ GM-Tg-bovg-IP3470-Ag-2; GM-Tg-equg-IP3470-Ag-1/ GM-Tg-equg-IP3470-Ag-2
Products Name CDKN2B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name CDKN2B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CDKN2B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.